ClinicalTrials.gg
WithdrawnNCT03370185BRIOUpdated Feb 28, 2023

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

A Phase 2 interventional study of Duvelisib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by SecuraBio. Withdrawn at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by SecuraBio · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Reassessing corporate priorities.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 2 under way, none of them phase 3. duvelisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
10th of 12
0 · median 11
Started
2018
with 1 other
Phase 2
3 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
5 of 12
SecuraBio

Among the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 8th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About duvelisib

duvelisib: first FDA approval 2018 (COPIKTRA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Leukemia
  • Lymphoma
  • Refractory
  • Relapse
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age.
  2. Diagnosis of CLL or SLL.
  3. Received at least one prior anti-cancer therapy for CLL or SLL.
  4. Previous exposure to BTKi and meet at least one of the criteria below:

    1. Progressive disease (PD) while receiving or within 6 months after completing BTKi therapy.
    2. Discontinued a BTKi therapy due to BTKi treatment- related intolerance.
  5. with a lymph node or tumor mass > 1.5 cm in at least one dimension.
  6. (ECOG) performance status ≤ 2.
  7. Resolution of toxicities due to prior BTKi therapy to acceptable level.
  8. Willingness of male and female patients to use medically acceptable methods of .
  9. Willing and able to participate in all required study evaluations and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Richter's transformation or prolymphocytic leukemia
  2. Uncontrolled hemolytic anemia or thrombocytopenia
  3. Received prior transplant
  4. Experienced PD or serious adverse events on a prior phosphoinositide-3-kinase (PI3K) inhibitor
  5. Known central nervous system involvement by CLL/SLL
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Duvelisib

    Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles

    Drug: Duvelisib

Interventions

  • Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Time frame: From start of treatment to first documented response, 2 cycles (58 days)

Secondary outcomes

  1. Treatment-Emergent adverse events (TEAEs) and changes in laboratory values

    Time frame: From start of treatment to end of treatment plus 30 days; 7 months

  2. Duration of response (DOR), defined as the time from the first documentation of response to the first documentation of PD or death due to any cause

    Time frame: Time from the first documentation of response to first documentation of progressive disease or death due to any cause, 6 months

  3. Progression-free survival (PFS), defined as the time from the first dose of study treatment to the first documentation of PD or death from any cause

    Time frame: Time from start of treatment to first documentation of progression or date of death from any cause, whichever came first, 4 months

  4. Disease control rate (DCR), defined as CR/CRi + PR/PRwL + stable disease (SD) ≥ 8 weeks

    Time frame: Greater than or equal to 8 weeks

07

Study locations

8 sites
  • Arizona Oncology
    Tempe, Arizona 85284, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Moores UC San Diego Cancer Center
    La Jolla, California 92093, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • QUEST Research Institute
    Royal Oak, Michigan 48073, United States
  • St. Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • Summit Medical Group
    Morristown, New Jersey 07932, United States
  • Medical Oncology Associates PS, WA
    Spokane, Washington 99208, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2018 (actual). Primary completion is estimated for Jun 2020, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2017
First posted
Dec 12, 2017
StartActual
Feb 12, 2018
Primary completionEst.
Jun 2020
CompletionEst.
Mar 2021
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03370185
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
Feb 12, 2018
Primary completion
Jun 2020 (estimated)
Completion
Mar 2021 (estimated)
Last update
Feb 28, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion